BeiGene's (HKG:6160, SHA:688235) loss narrowed to $151.9 million in the fourth quarter of 2024 from $367.6 million in the year-ago period.
Loss per share at the drug company narrowed to $0.11 from $0.27 in the previous year, according to a Thursday filing with the Hong Kong bourse.
Total revenue surged to $1.12 billion from $630.5 million a year earlier.
For 2025, full-year revenue is seen to range between $4.9 billion and $5.3 billion. It also forecasts positive GAAP operating income, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。